Ocjena teme:
  • 0 Glas (ova)- 0 Prosječno
  • 1
  • 2
  • 3
  • 4
  • 5
Pegasys - Pegintron ?? (opet ja...)
nađoh studiju da pegasys može pomoći nonresponderima na pegintron (tecumseh >Sad) i to sa nekom TURBO dozom 360μg/wk
E da mi je vidjeti onda nuspojave :uglystupid2: :crazy2: :idiot2: :uglystupid2:

Citat:Retreatment with Peginterferon Alfa-2a (Pegasys) Plus Ribavirin of Nonresponders to Peginterferon Alfa-2b (PegIntron) Plus Ribavirin
The REPEAT trial is assessing the efficacy/safety of peginterferon alfa-2a (Peg-IFNα-2a) [Pegasys] + ribavirin (RBV) in prior non-responders to peginterferon alfa-2b (Peg-IFNα-2b [PegIntron] /ribavirin. At Digestive Disease Week (DDW) 2006 in Los Angeles (May 20-25, 2006), Dr. N Gitlin reported outcomes in patients (pts) with cirrhosis/advanced fibrosis according to geographic region from a protocol-planned interim efficacy/safety analysis after 12 weeks (wks) of retreatment in the REPEAT trial.

Prior non-responders to ≥12wks of Peg-IFNα-2b/ribavirin who were HCV RNA positive throughout treatment were eligible.

950 pts were randomized to 1 of 4 groups: Peg-IFNα-2a 360μg/wk for 12wks then 180μg/wk for 60 or 36 wks (Arms A or B); Peg-IFNα-2a 180μg/wk for 72 or 48 wks (C or D).

All 942 pts treated received RBV 1000/1200mg/d. HCV RNA was measured by quantitative (≥600 IU/mL) or qualitative (≥50 IU/mL) PCR at baseline and after 12 wks' retreatment. Data from Arms A+B (Peg-IFNα-2a induction dose), and C+D (Peg-IFNα-2a standard dose) were combined.

Outcomes were assessed in pts with a local baseline histological diagnosis of cirrhosis/advanced fibrosis.

Results (Table)

Cirrhosis/advanced fibrosis was present in 133/469 pts (28.4%) receiving Peg-IFNα-2a 180μg/wk and 119/473 pts (25.2%) receiving Peg-IFNα-2a  360μg/wk.
Baseline characteristics were generally similar in the 2 groups. At wk 12, more pts with cirrhosis/advanced fibrosis receiving induction-dose Peg-IFNα-2a achieved an early virological response (EVR; HCV RNA undetectable, unquantifiable or ≥2-log10 drop), vs standard-dose Peg-IFNα-2a.
Virological response rates in pts with cirrhosis/advanced fibrosis were similar in US/Canadian and European/Brazilian pts across both treatment groups.

In conclusion, the authors write, “Induction-dose (360μg/wk) Peg-IFNα-2a  (Pegasys) + RBV (Copegus) is more effective than standard-dose (180μg/wk) Peg-IFNα-2a (Pegasys) + RBV over the first 12 wks of retreatment in pts with cirrhosis/advanced fibrosis who have previously failed to respond to Peg-IFNα-2b /ribavirin.”
“Outcomes in these pts do not appear to differ according to geographic region.”

Tablica: http://hivandhepatitis.com/2006icr/ddw/d...306_a.html (nisam uspjela pejstati)
‡HCV RNA ≥2-log10 drop or unquantifiable or undetectable

N. Gitlin, A. Di Bisceglie, P. Marcellin, and others.Peginterferon Alfa-2a (40KD) (PEGASYS&regWink Plus Ribavirin (RBV) (COPEGUS&regWink in Pegylated Interferon Alfa-2b (12KD)/Ribavirin Non-Responders with Cirrhosis/Advanced Fibrosis: Interim Analysis of the REPEAT Study. Abstract T1808.
Where is my Mind?


Korisnika pretražuje ovu temu: 1 Gost(iju)